Drug intelligence / Profile preview

Anti-ESBL IgY

Development stage
Unknown
Lead developer
Uppsala University
Modality
Antibody-Based Therapeutics
Administration
Oral
01

Overview

Anti-ESBL IgY is an oral biologic therapy composed of polyclonal chicken egg yolk-derived immunoglobulin Y (IgY) antibodies. It is specifically engineered to target and neutralize extended-spectrum beta-lactamase (ESBL)-producing bacteria, primarily *Klebsiella pneumoniae* and *Escherichia coli*, within the gastrointestinal tract. Developed by researchers at Uppsala University, the drug is intended to eradicate intestinal carriage of these antibiotic-resistant pathogens, thereby reducing the risk of endogenous infection and horizontal transmission. Although it reached Phase II clinical testing, the trial was terminated early due to challenges in patient recruitment and high mortality in the target population.

Other names
anti-ESBL IgY antibodiesavian polyclonal anti-ESBL IgY
02

Targets

pathogenic E. coli (Pathogenic Escherichia coli)

Beyond the preview

Go deeper on Anti-ESBL IgY.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anti-ESBL IgY.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call